The Transcatheter Aortic Valve Replacement Market involves the implantation of an artificial aortic valve using a catheter without any open-heart surgery. The procedure is performed through small incisions in the legs or neck instead of opening the chest and splitting the breastbone. Transcatheter heart valves (THVs) offer several advantages over surgical aortic valve replacement like reduced risks of stroke, bleeding events, shorter hospital stays, and faster recovery times. The procedures require minimal use of anesthesia and a shorter hospital stay and recovery period compared to open-heart surgeries.

The global transcatheter aortic valve replacement market is estimated to be valued at USD 6.71 Bn in 2024 and is expected to reach USD 10.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Key Takeaways

Key players operating in the Transcatheter Aortic Valve Replacement market are Edwards Lifesciences Corp., Medtronic Plc., Abbott Laboratories., Boston Scientific Corp., MicroPort Scientific Corp., JenaValve Technology GmbH., Cardiovascular Systems, Inc., Symetis SA., Lepu Medical Technology Co., Ltd., Terumo Corporation., St. Jude Medical (now part of Abbott)., AtriCure, Inc., Vascular Solutions, Inc., Biotronik SE & Co. KG., and Cook Medical. These players are involved in new product launches, partnerships, and regional expansion to gain market share.

The growing geriatric population suffering from aortic stenosis and preference of patients for minimally invasive surgeries compared to open-heart surgeries are driving the Transcatheter Aortic Valve Replacement Market Growth. Manufacturers are expanding their operations globally with presence across major markets to cater to the increasing demand. Regions with high incidence of aortic stenosis like North America, Europe, and Asia Pacific are attracting significant investments by industry players.

Get More Insights on- Transcatheter Aortic Valve Replacement Market